Lyophilization USA Conference 2018

SMi Group15 - 16 November 2018, New Jersey, USA.
16% of the top 100 pharmaceutical drugs and 35% of biologic drugs are lyophilized. With more than 30% of the FDA-approved parenterals lyophilized and soon more than half injectable drugs to require lyophilization there is ample room for standardization and expansion of the lyophilization process in pharmaceuticals.

The 4th Annual Lyophilization USA conference will be analysing technological advantages, regulatory challenges and unmet needs within lyophilization.

Day 1 of the Conference (November 15) will be covering Novel Techniques and Advances, Regulatory Challenges and Analytical Processes; Continuous monitoring of sublimation rate for individual containers & Reconstitution challenges of lyophilized highly concentrated protein products; Freeze dryer characterization and application to drug product development and scale up; Formulation and excipient selection for lyo product development of vaccines

Day 2 of the Conference (November 16) will be focusing on challenges that process of lyophilization brings to pharmaceutical and biotechnology companies; Oncobiologics on Freezing of biologics formulations - impact on stability; Panel Discussion on Process modelling and simulation; and also looking into alternatives to conventional methods with the Keynote Address on vacuum-foam drying and key action points on future directions in lyophilization

Featured Speakers

  • Alex Langford - Pfizer
  • Colin Campbell - Elusys Therapeutics
  • Dena Flamm - Optima Machinery Corporation
  • Fabrice Schlegel - Amgen
  • Hiten Gutka - Oncobiologics
  • Morrisa Jones - Merck
  • Alina Alexeenko - Purdue University
  • Rui Fang - Merck Research Laboratories
  • Sushma Kommareddy - Takeda
  • Timothy McCoy - Sanofi

Enhance your knowledge on controlled nucleation, available PAT's and the future of flexible PAT processes, and alternative freeze dryer technologies including spray drying, spin freeze-drying and microwave drying at the Workshop A on November 14 hosted by Alexander Tambovzev and Dena Flamm of Optima Pharma

Are you new to the area of freeze-drying/lyophilization? Sign up to attend the Workshop B on November 14 hosted by Robin Bogner, University of Connecticut and gain an understanding of the essential aspects of freeze-drying.

Further details at http://www.lyophilization-usa.com/wpnWL

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Chemists characterize the fatal fungus among us

Life-threatening fungal infections affect more than two million people worldwide. Effective antifungal medications are very limited. Until now, one of the major challenge...

FDA approves first cancer drug through new oncolog…

The U.S. Food and Drug Administration today approved Kisqali (ribociclib) in combination with an aromatase inhibitor for the treatment of pre/perimenopausal or postmenopa...

Discovery of kidney cancer driver could lead to ne…

University of North Carolina Lineberger Comprehensive Cancer Center scientists have uncovered a potential therapeutic target for kidney cancers that have a common genetic...

The immune system: T cells are built for speed

Without T cells, we could not survive. They are a key component of our immune system and have highly sensitive receptors on their surface that can detect pathogens. The e...

Pfizer initiates pivotal Phase 3 program for inves…

Pfizer Inc. (NYSE:PFE) and Spark Therapeutics (NASDAQ:ONCE) announced today that Pfizer initiated a Phase 3 open-label, multi-center, lead-in study (NCT03587116) to evalu...

FDA approves first targeted treatment for patients…

The U.S. Food and Drug Administration today approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (...

Sanofi and REVOLUTION Medicines launch global part…

Sanofi and REVOLUTION Medicines, Inc. today announced an exclusive worldwide partnership to develop and commercialize targeted therapies, based on the biology of the cell...

Novartis renews drug donation of Egaten® (triclabe…

Novartis reaffirms its commitment to the fight against liver fluke (fascioliasis), signing a renewed memorandum of understanding with the World Health Organization (WHO) ...

Women and older people under-represented in drug t…

Trying to determine how best to treat a patient, doctors often look to randomized clinical trials to guide their choice of what drug to prescribe. One of the most common ...

New findings suggest allergic responses may protec…

The components of the immune system that trigger allergic reactions may also help protect the skin against cancer, suggest new findings. The research, led by Imperial Col...

FDA grants Breakthrough Therapy Designation for Ro…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Tecentriq® (atezolizumab) i...

Novartis marks a new era for migraine patients wit…

Novartis announced today that the European Commission (EC) approved Aimovig® (erenumab) for the prevention of migraine in adults experiencing four or more migraine days p...